-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, McAR2AL32RP/DhbM4FLipXo5jBXKN4C+BZTsoW81OuU4oQDokS69oCAZj0vrq1uD 0+QqTp6LytjQv95ofBWxDg== 0000947871-02-002124.txt : 20021031 0000947871-02-002124.hdr.sgml : 20021031 20021031172251 ACCESSION NUMBER: 0000947871-02-002124 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20021031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-89355 FILM NUMBER: 02805532 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2124496202 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER FL 12 CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_103102-biotech.txt PROSPECTUS SUPPLEMENT FILED PURSUANT TO RULE NO. 424(b)(3) PROSPECTUS SUPPLEMENT REGISTRATION NO. 333-89355 (To Prospectus dated March 12, 2002) [HOLDRS BIOTECH LOGO] 1,000,000,000 Depositary Receipts Biotech HOLDRS (SM) Trust This prospectus supplement supplements information contained in the prospectus dated March 12, 2002 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust. The share amounts specified in the table on page 13 of the base prospectus shall be replaced with the following:
Share Primary Name of Company (1) Ticker Amounts Trading Market ------------------- ------ ------- -------------- Affymetrix, Inc. AFFX 4 NASDAQ Alkermes, Inc. ALKS 4 NASDAQ Amgen Inc.(1) AMGN 64.48 NASDAQ Applera Corporation--Applied Biosystems Group ABI 18 NYSE Applera Corporation--Celera Genomics Group CRA 4 NYSE Biogen, Inc. BGEN 13 NASDAQ Chiron Corporation CHIR 16 NASDAQ Enzon, Inc. ENZN 3 NASDAQ Genentech, Inc. DNA 44 NYSE Genzyme Corporation GENZ 14 NASDAQ Gilead Sciences, Inc. GILD 16 NASDAQ Human Genome Sciences, Inc. HGSI 8 NASDAQ ICOS Corporation ICOS 4 NASDAQ IDEC Pharmaceuticals Corporation IDPH 12 NASDAQ MedImmune, Inc. MEDI 15 NASDAQ Millennium Pharmaceuticals, Inc. MLNM 12 NASDAQ QLT Inc. QLTI 5 NASDAQ Sepracor Inc. SEPR 6 NASDAQ Shire Pharmaceuticals Group p.l.c. SHPGY 6.8271 NASDAQ
-------------------- (1) On July 17, 2002 Amgen Inc. completed its merger with Immunex Corp., both components of Biotech HOLDRS. As a result of the merger, in exchange for each share of Immunex, shareholders received $4.50 in cash and .44 shares of Amgen stock. Immunex Corp. is no longer included in Biotech HOLDRS. The share amount of Amgen Inc. represented by a round-lot of 100 Biotech HOLDRS is now 64.48. The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions. The date of this prospectus supplement is September 30, 2002. -----END PRIVACY-ENHANCED MESSAGE-----